ClinicalTrials.gg
CompletedNCT04431310Updated Nov 12, 2026

Seroconversion Among Staff at a Large Acute Care Hospital in Denmark During the COVID-19 Pandemic

An observational study in Covid-19, Health Personnel and Personnel, Hospital, sponsored by Nordsjaellands Hospital. Completed at 2 sites in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Nordsjaellands Hospital · Observational

How we know

Updated Nov 12, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 99 studies in COVID-19 with a site in Denmark — 10 open to participants now, 12 under way, 3 of them phase 3. COVID-19 · Denmark.

Enrollment
24th of 43
300 · median 417
Started
2020
with 54 others
Observational
43 of 99
5 open now
Registered
22nd of 99
by date
Lead sponsor
4 of 99
Nordsjaellands Hospital

Among the 99 studies in COVID-19 with a site in Denmark, this one is the 24th largest by enrollment of the 43 observational ones that give a count, is one of 55 that started in 2020, is one of 43 observational ones, and was the 22nd registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

10 of the 99 studies in COVID-19 with a site in Denmark are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in COVID-19 with a site in Denmark, or all of them as a file.
02

Study summary

The aim of this study is to apply serology testing methods for SARS-CoV2 antibodies in samples collected from HCWs in an acute hospital. This will enable the identification of those who are protected and non-infectious for SARS-CoV2 and those who are seronegative and therefore potentially susceptible and infectious on patient contact. Prospective testing will provide data on the acquisition of SARS-CoV2 infections among HCWs and associated risk factors for transmission during a pandemic at an acute care hospital facility in the capital region of Denmark.

Hypothesis: Serial seroconversion measurements in hospital employees improve the organization of the clinical treatment and care during the COVID-19 pandemic at Nordsjællands Hospital and Nykøbing Falster County Hospital.

Read the detailed description

The study is a prospective cohort study. Weekly (in the first phase) and bi-weekly (in the second phase) serum samples will be drawn and shipped bi-weekly to laboratory collaborators in United Kingdom for antibody analyses during the course of the local epidemic, expected to last 10-12 weeks or more. After the cease of the epidemic serum will be drawn in 3-monthly intervals in a smaller group of seroconverted volunteers to follow the long-lasting immunity of SARS-CoV-2 infection up to 5 years post-pandemic.

Nurses, medical doctors, biomedical laboratory scientists, social health care assistants, and few healthcare administrators (as controls) will be invited for enrolment. In hospitals, all departments with staff that are in physical contact with patients during the pandemic will be invited to participate in the study.

03

Conditions studied

  • Covid-19
  • Health Personnel
  • Personnel, Hospital

Keywords

  • healthcare workers
  • health care workers
  • hcw
  • seroconversion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Health care workers at two Danish hospitals

Eligibility criteria

Inclusion Criteria: hospital employee

-

Exclusion Criteria: none

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Serial seroconversion measurements in hospital employees

    Serial seroconversion measurements in hospital employees during the COVID-19 pandemic

    Other: Serial seroconversion measurements in hospital employees during the COVID-19 pandemic

Interventions

  • OtherSerial seroconversion measurements in hospital employees during the COVID-19 pandemic

    The aim of this study is to apply serology testing methods for SARS-CoV2 antibodies in samples collected from HCWs in an acute hospital.

06

What researchers measure

Primary outcomes

  1. Serology testing for specific COVID-19

    IgM and IgG (Covid-19 antibodies)

    Time frame: From baseline to follow up at four years

Secondary outcomes

  1. SARS-CoV-2 infection

    Swab, SARS-CoV-2

    Time frame: From baseline to follow up at three months

Other outcomes

  1. Co-variates

    Age, gender, employment details, smoking, chronic diseases

    Time frame: At baseline

07

Study locations

2 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Sep 2023, 41 months.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 41 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Aug 2025 → Sep 2023 and completion Aug 2025 → Sep 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2020
First posted
Jun 16, 2020
StartActual
Mar 27, 2020
Primary completionActual
Sep 13, 2023was Aug 2025
CompletionActual
Sep 13, 2023was Aug 2025
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 12, 2026
Primary completion
Aug 1, 2025→Sep 13, 2023 (actual)
Nov 12, 2026
Study completion
Aug 1, 2025→Sep 13, 2023 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Completed
    Primary completion Aug 1, 2025→Sep 13, 2023 (now actual)
    Study completion Aug 1, 2025→Sep 13, 2023 (now actual)
    + 3 other changes: criteria formatting, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04431310
Lead sponsor
Nordsjaellands Hospital
Collaborators
University of Oxford, Nykøbing Falster County Hospital
Responsible party
Thea Kølsen Fischer (Professor, Nordsjaellands Hospital) — Principal investigator
First posted
Jun 16, 2020
Start date
Mar 27, 2020
Primary completion
Sep 13, 2023
Completion
Sep 13, 2023
Last update
Nov 12, 2026

Study contacts

Thea K Fischer, professor
principal investigator · Nordsjaellands Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion